search
Back to results

A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures

Primary Purpose

Arthroscopy, Bunionectomy, Osteotomy

Status
Terminated
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
fospropofol disodium
Sponsored by
Eisai Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arthroscopy focused on measuring AQUAVAN® Injection, Midazolam, Minor surgical procedures, Sedation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient provided signed/dated Informed Consent and HIPAA Authorization after receiving a full explanation of the extent and nature of the study. Patient was at least 18 years of age at the time of screening. (Prior to Amendment 1, dated 03 February 2005, this criterion restricted enrollment to patients who were ≥18 and ≤65 years of age. To ensure that safe dosing levels were administered to patients >65 years of age, AQUAVAN and midazolam dosing levels were reduced when compared with patients between 18 and 65 years of age, inclusive. The majority of patients were enrolled prior to 03 February 2005.) Female patient must have been surgically sterile, postmenopausal, or not pregnant or lactating, and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predosing periods. Patient met the American Society of Anesthesiologists (ASA) Physical Status Classification System of I to III. Patient may have been an inpatient or outpatient scheduled to undergo a single minor surgical and/or therapeutic procedure. Exclusion Criteria: Patient had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine. Patient did not meet nils per os (NPO) status per ASA Guideline or institution's guideline. Patient had condition(s) that, in the opinion of the Investigator, could interfere with appropriate airway management. Patient had participated in an investigational drug study within 1 month prior to study start. Patient had a history of mental or visual impairment that would not permit successful measurement of cognitive evaluations. Patient was unwilling to adhere to pre- and postprocedural instructions. The use of fentanyl or midazolam was contraindicated for the patient. Patient had experienced multiple concurrent injuries or trauma. Patient was scheduled to undergo multiple same-day procedures (eg, bunionectomies on both feet).

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Successful Sedation of Subjects, Defined for a Subject as Having 3 Consecutive Scores ≤ 4 on the Modified Observer's Assessment of Alertness/Sedation Scale and Completing the Procedure w/o Alternative Sedative Medications/w/o Manual/Mechanical Ventilation
    The Modified OAA/S (MOAA/S) scale is based on a validated, 6-point rating scale. Scores are not combined. Score 5 (alert) -- responds readily to name spoken in normal tone Score 4 -- Lethargic response to name spoken in normal tone Score 3 -- Responds only after name is called loudly and/or repeatedly Score 2 -- Responds only after mild prodding or shaking Score 1 -- Responds only after painful trapezius squeeze Score 0 -- Does not respond to painful trapezius squeeze

    Secondary Outcome Measures

    Time to Fully Alert From the End of the Procedure
    Time to Fully Alert, defined as the time to the first of 3 consecutive Modified OAA/S scores of 5 from the end of the surgical procedure, was summarized.

    Full Information

    First Posted
    September 13, 2005
    Last Updated
    December 22, 2014
    Sponsor
    Eisai Inc.
    Collaborators
    PPD, Covance
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00209560
    Brief Title
    A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures
    Official Title
    A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Terminated
    Study Start Date
    October 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    March 2005 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Eisai Inc.
    Collaborators
    PPD, Covance

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to determine the safety, tolerability, and efficacy of AQUAVAN® Injection when used for mild-to-moderate sedation in patients undergoing minor surgical procedures.
    Detailed Description
    Randomized, open label, multi-center,midazolam adaptive dose ranging study, in which several dose levels of AQUAVAN® Injection and fentanyl citrate injection will be investigated to produce a desired sedation level in patients undergoing minor surgical and/or therapeutic procedures. A desired sedative dose/dose range and dosing paradigm will be identified based on pre-set criteria using the Modified Observer's Assessment of Alertness/Sedation (OAA/S). The desired sedative dose/dose range and dosing paradigm of AQUAVAN® Injection is defined as one that consistently provides mild to moderate sedation (Modified OAA/S between 2 and 4 inclusive) in majority of patients who are pre-medicated with fentanyl citrate injection. Midazolam is the most widely used i.v. agent for minimal-to-moderate sedation. The dose range of midazolam to induce minimal to moderate sedation was based on standard clinical practice. [new paragraph] All patients were pre-medicated with fentanyl citrate as an analgesic. The outpatient setting has become increasingly popular for various types of medical procedures requiring sedation. In outpatient minor surgical procedures, sedation agents are used to provide mild-to-moderate sedation and are used with other medicines for pain management. Surgeons have searched for alternative treatments to use in the outpatient setting that would provide a faster recovery time with minimal post-procedure amnesia. This injection is used following pretreatment with fentanyl citrate for pain management.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Arthroscopy, Bunionectomy, Osteotomy, Carpal Tunnel
    Keywords
    AQUAVAN® Injection, Midazolam, Minor surgical procedures, Sedation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    168 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    fospropofol disodium
    Primary Outcome Measure Information:
    Title
    Successful Sedation of Subjects, Defined for a Subject as Having 3 Consecutive Scores ≤ 4 on the Modified Observer's Assessment of Alertness/Sedation Scale and Completing the Procedure w/o Alternative Sedative Medications/w/o Manual/Mechanical Ventilation
    Description
    The Modified OAA/S (MOAA/S) scale is based on a validated, 6-point rating scale. Scores are not combined. Score 5 (alert) -- responds readily to name spoken in normal tone Score 4 -- Lethargic response to name spoken in normal tone Score 3 -- Responds only after name is called loudly and/or repeatedly Score 2 -- Responds only after mild prodding or shaking Score 1 -- Responds only after painful trapezius squeeze Score 0 -- Does not respond to painful trapezius squeeze
    Time Frame
    Sedation success was assessed at 2 minute intervals until the end of the procedure
    Secondary Outcome Measure Information:
    Title
    Time to Fully Alert From the End of the Procedure
    Description
    Time to Fully Alert, defined as the time to the first of 3 consecutive Modified OAA/S scores of 5 from the end of the surgical procedure, was summarized.
    Time Frame
    At 2-minute intervals from the end of the procedure until the subject met the criteria for Fully Alert status

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patient provided signed/dated Informed Consent and HIPAA Authorization after receiving a full explanation of the extent and nature of the study. Patient was at least 18 years of age at the time of screening. (Prior to Amendment 1, dated 03 February 2005, this criterion restricted enrollment to patients who were ≥18 and ≤65 years of age. To ensure that safe dosing levels were administered to patients >65 years of age, AQUAVAN and midazolam dosing levels were reduced when compared with patients between 18 and 65 years of age, inclusive. The majority of patients were enrolled prior to 03 February 2005.) Female patient must have been surgically sterile, postmenopausal, or not pregnant or lactating, and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predosing periods. Patient met the American Society of Anesthesiologists (ASA) Physical Status Classification System of I to III. Patient may have been an inpatient or outpatient scheduled to undergo a single minor surgical and/or therapeutic procedure. Exclusion Criteria: Patient had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine. Patient did not meet nils per os (NPO) status per ASA Guideline or institution's guideline. Patient had condition(s) that, in the opinion of the Investigator, could interfere with appropriate airway management. Patient had participated in an investigational drug study within 1 month prior to study start. Patient had a history of mental or visual impairment that would not permit successful measurement of cognitive evaluations. Patient was unwilling to adhere to pre- and postprocedural instructions. The use of fentanyl or midazolam was contraindicated for the patient. Patient had experienced multiple concurrent injuries or trauma. Patient was scheduled to undergo multiple same-day procedures (eg, bunionectomies on both feet).
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    James Jones, MD, PharmD
    Organizational Affiliation
    Eisai Inc.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures

    We'll reach out to this number within 24 hrs